Buch, Englisch, 384 Seiten
Pharmaceutical Patents and the Experience of Brazil
Buch, Englisch, 384 Seiten
ISBN: 978-94-035-2882-3
Verlag: Kluwer Law International
- how “evergreening” and “trivial patents” undermine public health and access to medicines;
- ways of correcting abuses of patent rights and controlling quality of patents; and
- the discourse on health as a human right.
Along with her examination of ANVISA reports, the author analyzes how Article 229-C LPI, which introduced the need of ANVISA’s prior consent to the patent grant of pharmaceuticals in Brazil, has been interpreted in Brazilian case law. Interviews with Brazilian experts are also included. In its commitment to harmonizing patent rights and the right to access of affordable medicines, Brazil’s patent system for pharmaceuticals stands out as a workable response to the basic problem of access to medicines in the developing world. By describing the successes and failures in the Brazilian policy of promoting drug access, this book helps policymakers in developing and emerging countries to better explore TRIPS flexibilities when dealing with similar problems, and provides practitioners in the law of the World Trade Organization, patent law, competition law, and health law with a guide to how a more equitable pharmaceutical patenting system could work in practice.
Autoren/Hrsg.
Fachgebiete
- Rechtswissenschaften Internationales Recht und Europarecht Internationales Recht Internationales Handels-, Wirtschafts- und Gesellschaftsrecht
- Rechtswissenschaften Ausländisches Recht Mittel-/Südamerika
- Rechtswissenschaften Internationales Recht und Europarecht Internationales Recht Internationaler Gewerblicher Rechtsschutz, Medien-, IT- und Urheberrecht